IgM-enriched IVIG

Phase 3Small molecule

FFakultas Kedokteran Universitas Indonesia

IgM-enriched IVIG is one of 14 small molecule programs targeting Neonatal sepsis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neonatal SepsisActive, not recruiting

Neonatal SepsisPhase 3

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Neonatal Sepsis

#DrugCompanyPhaseTrials

Peridex

DDexcel Pharma Technologies Ltd.

Approved

—2

Merrem

BB. Braun Medical Inc.

Monurol

Vancocin

HHikma Pharmaceuticals LLC

Approved

—5

Lactoferrin

UUniversità degli Studi di Ferrara

Approved

1 6

Trental

VValidus Pharmaceuticals

Phase 3

1 7

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 8

Ivig

Argenx

Phase 3

1 9

N-Acetyl Cyteien

SStanford University

Phase 3

1 10

Singulair

AstraZeneca

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neonatal sepsis1 trial

IgM-Enriched Immunoglobulin for Neonatal Sepsis

Unknown status·FFakultas Kedokteran Universitas Indonesia·Phase 3·NCT04041765·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IgM-enriched IVIG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IgM-enriched IVIG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IgM-enriched IVIG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fakultas Kedokteran Universitas Indonesia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFakultas Kedokteran Universitas Indonesia

IgM-enriched IVIG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neonatal sepsis1 trial

References

Drug Info

Quick Facts

Related News